DK1076704T3 - IL-2-selektive agonister og antagonister - Google Patents
IL-2-selektive agonister og antagonisterInfo
- Publication number
- DK1076704T3 DK1076704T3 DK99924232T DK99924232T DK1076704T3 DK 1076704 T3 DK1076704 T3 DK 1076704T3 DK 99924232 T DK99924232 T DK 99924232T DK 99924232 T DK99924232 T DK 99924232T DK 1076704 T3 DK1076704 T3 DK 1076704T3
- Authority
- DK
- Denmark
- Prior art keywords
- antagonists
- selective agonists
- agonists
- selective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8008098A | 1998-05-15 | 1998-05-15 | |
PCT/US1999/010643 WO1999060128A1 (en) | 1998-05-15 | 1999-05-13 | Il-2 selective agonists and antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1076704T3 true DK1076704T3 (da) | 2007-03-12 |
Family
ID=22155135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99924232T DK1076704T3 (da) | 1998-05-15 | 1999-05-13 | IL-2-selektive agonister og antagonister |
Country Status (39)
Country | Link |
---|---|
EP (1) | EP1076704B1 (zh) |
JP (1) | JP4276783B2 (zh) |
KR (1) | KR100607609B1 (zh) |
CN (2) | CN101319247B (zh) |
AR (1) | AR020322A1 (zh) |
AT (1) | ATE351907T1 (zh) |
AU (1) | AU759697B2 (zh) |
BG (1) | BG65139B1 (zh) |
BR (1) | BRPI9910504B1 (zh) |
CA (1) | CA2327349C (zh) |
CO (1) | CO5070701A1 (zh) |
CU (2) | CU23273B7 (zh) |
CY (1) | CY1107533T1 (zh) |
CZ (1) | CZ302071B6 (zh) |
DE (1) | DE69934881T2 (zh) |
DK (1) | DK1076704T3 (zh) |
DZ (1) | DZ2788A1 (zh) |
ES (1) | ES2281175T3 (zh) |
HK (1) | HK1039963B (zh) |
HN (1) | HN1999000075A (zh) |
HU (1) | HU226142B1 (zh) |
IL (2) | IL139136A0 (zh) |
MY (1) | MY130274A (zh) |
NO (1) | NO329235B1 (zh) |
NZ (1) | NZ508098A (zh) |
PA (1) | PA8472601A1 (zh) |
PE (1) | PE20000475A1 (zh) |
PL (1) | PL201675B1 (zh) |
PT (1) | PT1076704E (zh) |
RO (1) | RO122150B1 (zh) |
RU (1) | RU2235729C2 (zh) |
SI (1) | SI20643B (zh) |
SK (1) | SK288100B6 (zh) |
SV (1) | SV1999000061A (zh) |
TN (1) | TNSN99090A1 (zh) |
TR (1) | TR200003354T2 (zh) |
TW (1) | TWI223663B (zh) |
UA (1) | UA73719C2 (zh) |
WO (1) | WO1999060128A1 (zh) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058456A2 (en) | 1999-03-30 | 2000-10-05 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinacious compounds |
EP1935431A3 (en) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Cancer treatments by using a combination of an antibody against her2 and interleukin-2 |
US6689353B1 (en) * | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
US7723102B2 (en) * | 2000-09-28 | 2010-05-25 | Bayer Corporation | Enhanced transfection system |
MY139948A (en) * | 2000-09-28 | 2009-11-30 | Bayer Corp | Enhanced transfection system |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
BR0214650A (pt) * | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
DE602004031341D1 (de) | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
ATE500267T1 (de) | 2003-07-21 | 2011-03-15 | Transgene Sa | Multifunktionelle cytokine |
EP1682178B8 (en) | 2003-11-04 | 2010-09-01 | Novartis Vaccines and Diagnostics, Inc. | Methods of therapy for cancers expressing the cd40 antigen |
WO2005085282A1 (en) * | 2004-02-27 | 2005-09-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity |
WO2005091956A2 (en) * | 2004-03-05 | 2005-10-06 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
CN101244261B (zh) * | 2008-03-10 | 2010-09-15 | 山东大学 | 一种含未复性重组蛋白的生物制剂及其制备方法与应用 |
DE102008023820A1 (de) * | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
JP5766124B2 (ja) | 2009-01-21 | 2015-08-19 | アムジェン インコーポレイテッド | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
KR102472497B1 (ko) | 2010-11-12 | 2022-11-29 | 넥타르 테라퓨틱스 | Il-2 부분 및 중합체의 접합체 |
EP3211001B1 (en) * | 2010-12-22 | 2020-10-07 | The Board of Trustees of the Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
CN105440123B (zh) | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
WO2012119093A1 (en) * | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
US10781242B2 (en) | 2013-09-24 | 2020-09-22 | Medicenna Therapeutics Inc. | Interleukin-2 fusion proteins and uses thereof |
EP3102595B1 (en) | 2014-02-06 | 2018-11-07 | F.Hoffmann-La Roche Ag | Interleukin-2 fusion proteins and uses thereof |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
EP3134102B1 (en) | 2014-04-24 | 2019-07-03 | The Board of Trustees of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
HUE051414T2 (hu) | 2014-08-11 | 2021-03-01 | Delinia Inc | Módosított IL-2 változatok, amelyek szelektíven aktiválnak regulátor T sejteket, autoimmun betegségek kezelésére |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
US20200316118A1 (en) * | 2016-05-19 | 2020-10-08 | The General Hospital Corporation | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
RU2756236C2 (ru) | 2016-06-20 | 2021-09-28 | Кимаб Лимитед | PD-L1 специфические антитела |
JP7206190B2 (ja) * | 2016-06-22 | 2023-01-17 | ダヴィド・クラッツマン | 遺伝的に修飾されたtリンパ球 |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
US11077172B2 (en) | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
CA3044416A1 (en) * | 2016-12-13 | 2018-06-21 | Delinia, Inc. | Multivalent regulatory t cell modulators |
AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
SG11201909949XA (en) | 2017-05-24 | 2019-11-28 | Pandion Therapeutics Inc | Targeted immunotolerance |
WO2018215938A1 (en) * | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
US11542312B2 (en) | 2017-06-19 | 2023-01-03 | Medicenna Therapeutics, Inc. | IL-2 superagonists in combination with anti-PD-1 antibodies |
MX2020001336A (es) * | 2017-08-03 | 2020-08-20 | Synthorx Inc | Conjugados de citoquina para el tratamiento de enfermedades autoinmunes. |
AU2018372167B2 (en) * | 2017-11-21 | 2023-12-07 | The Board Of Trustees Of The Leland Stanford Junior University | Partial agonists of interleukin-2 |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
KR20200100098A (ko) | 2017-12-19 | 2020-08-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
US11534479B2 (en) | 2018-02-16 | 2022-12-27 | Iltoo Pharma | Use of interleukin 2 for treating Sjögren's syndrome |
IL277572B2 (en) | 2018-03-28 | 2024-05-01 | Ascendis Pharma Oncology Div A/S | IL-2 conjugates |
AU2019244091B2 (en) | 2018-03-28 | 2023-12-07 | Bristol-Myers Squibb Company | Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use |
WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
CN112771072A (zh) * | 2018-07-24 | 2021-05-07 | 生物技术Rna制药有限公司 | Il2激动剂 |
EP3836954A1 (en) | 2018-08-13 | 2021-06-23 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
BR112020015030A2 (pt) * | 2018-09-17 | 2021-03-16 | Gi Innovation, Inc. | Proteína de fusão compreendendo a proteína il-2 e a proteína cd80 e uso da mesma |
TW202034945A (zh) | 2018-12-21 | 2020-10-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種人白細胞介素2變體或其衍生物 |
TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向MAdCAM之免疫耐受性 |
TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2激動劑 |
AU2020328038A1 (en) * | 2019-08-13 | 2022-03-31 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
WO2021116444A1 (en) | 2019-12-12 | 2021-06-17 | Iltoo Pharma | Interleukin 2 chimeric constructs |
KR20220114595A (ko) | 2019-12-17 | 2022-08-17 | 암젠 인크 | 치료에서의 사용을 위한 이중 인터류킨-2/tnf 수용체 효현제 |
AU2021206449A1 (en) | 2020-01-10 | 2022-07-21 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
KR102653906B1 (ko) | 2020-01-14 | 2024-04-03 | 신테카인, 인크. | 편향된 il2 뮤테인 방법 및 조성물 |
EP4107187A1 (en) | 2020-02-21 | 2022-12-28 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
CA3175717A1 (en) | 2020-03-19 | 2021-09-23 | Innovent Biologics (Suzhou) Co., Ltd. | Interleukin-2 mutant and use thereof |
EP4130027A1 (en) * | 2020-03-31 | 2023-02-08 | Hanmi Pharm. Co., Ltd. | Novel immunoactive interleukin 2 analog |
EP4161956A1 (en) | 2020-06-03 | 2023-04-12 | Ascendis Pharma Oncology Division A/S | Il-2 sequences and uses thereof |
WO2022094275A1 (en) | 2020-10-29 | 2022-05-05 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
CN114507643A (zh) * | 2020-10-29 | 2022-05-17 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-2的多能干细胞衍生物及应用 |
CN113308477A (zh) * | 2021-04-08 | 2021-08-27 | 华南农业大学 | 一种鸭il-2基因真核表达重组质粒及其制备方法 |
CA3233075A1 (en) | 2021-09-22 | 2023-03-30 | Fortvita Biologics (Singapore) Pte. Ltd. | Interleukin-2 mutant and fusion protein thereof |
AU2022360645A1 (en) | 2021-10-06 | 2024-05-02 | Assistance Publique - Hôpitaux De Paris | Interleukin 2 chimeric constructs with targeting specificity to inflamed tissues |
CN114875069B (zh) * | 2022-04-22 | 2023-09-15 | 四川大学 | 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途 |
WO2023245097A2 (en) * | 2022-06-16 | 2023-12-21 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
WO2024056154A1 (en) | 2022-09-12 | 2024-03-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin-2 for use in treating autism spectrum disorder |
FR3140287A1 (fr) | 2022-10-03 | 2024-04-05 | Arkema France | Procede de granulation de composes azoiques et granules obtenus |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
-
1999
- 1999-05-12 DZ DZ990088A patent/DZ2788A1/xx active
- 1999-05-13 HU HU0101948A patent/HU226142B1/hu unknown
- 1999-05-13 DE DE69934881T patent/DE69934881T2/de not_active Expired - Lifetime
- 1999-05-13 TR TR2000/03354T patent/TR200003354T2/xx unknown
- 1999-05-13 PE PE1999000399A patent/PE20000475A1/es not_active Application Discontinuation
- 1999-05-13 CA CA2327349A patent/CA2327349C/en not_active Expired - Lifetime
- 1999-05-13 RO ROA200001123A patent/RO122150B1/ro unknown
- 1999-05-13 CN CN2007101609093A patent/CN101319247B/zh not_active Expired - Lifetime
- 1999-05-13 AR ARP990102269A patent/AR020322A1/es active IP Right Grant
- 1999-05-13 KR KR1020007012747A patent/KR100607609B1/ko not_active IP Right Cessation
- 1999-05-13 ES ES99924232T patent/ES2281175T3/es not_active Expired - Lifetime
- 1999-05-13 AT AT99924232T patent/ATE351907T1/de active
- 1999-05-13 PA PA19998472601A patent/PA8472601A1/es unknown
- 1999-05-13 CZ CZ20004213A patent/CZ302071B6/cs not_active IP Right Cessation
- 1999-05-13 SK SK1724-2000A patent/SK288100B6/sk not_active IP Right Cessation
- 1999-05-13 BR BRPI9910504A patent/BRPI9910504B1/pt not_active IP Right Cessation
- 1999-05-13 IL IL13913699A patent/IL139136A0/xx unknown
- 1999-05-13 AU AU40784/99A patent/AU759697B2/en not_active Expired
- 1999-05-13 EP EP99924232A patent/EP1076704B1/en not_active Expired - Lifetime
- 1999-05-13 WO PCT/US1999/010643 patent/WO1999060128A1/en active IP Right Grant
- 1999-05-13 RU RU2000131593/04A patent/RU2235729C2/ru active
- 1999-05-13 TN TNTNSN99090A patent/TNSN99090A1/fr unknown
- 1999-05-13 NZ NZ508098A patent/NZ508098A/en not_active IP Right Cessation
- 1999-05-13 PL PL344407A patent/PL201675B1/pl unknown
- 1999-05-13 SI SI9920034A patent/SI20643B/sl active Search and Examination
- 1999-05-13 UA UA2000127206A patent/UA73719C2/uk unknown
- 1999-05-13 PT PT99924232T patent/PT1076704E/pt unknown
- 1999-05-13 CN CNB998086509A patent/CN100366742C/zh not_active Expired - Lifetime
- 1999-05-13 DK DK99924232T patent/DK1076704T3/da active
- 1999-05-13 JP JP2000549735A patent/JP4276783B2/ja not_active Expired - Lifetime
- 1999-05-14 TW TW088107812A patent/TWI223663B/zh not_active IP Right Cessation
- 1999-05-14 MY MYPI99001912A patent/MY130274A/en unknown
- 1999-05-14 CO CO99030158A patent/CO5070701A1/es unknown
- 1999-05-14 HN HN1999000075A patent/HN1999000075A/es unknown
- 1999-05-14 SV SV1999000061A patent/SV1999000061A/es active IP Right Grant
-
2000
- 2000-10-18 IL IL139136A patent/IL139136A/en not_active IP Right Cessation
- 2000-11-08 BG BG104929A patent/BG65139B1/bg unknown
- 2000-11-14 NO NO20005762A patent/NO329235B1/no not_active IP Right Cessation
- 2000-11-15 CU CU20000257A patent/CU23273B7/es not_active IP Right Cessation
-
2002
- 2002-02-21 HK HK02101283.2A patent/HK1039963B/zh not_active IP Right Cessation
- 2002-06-19 CU CU20020125A patent/CU23272A1/es not_active IP Right Cessation
-
2007
- 2007-03-09 CY CY20071100330T patent/CY1107533T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1076704T3 (da) | IL-2-selektive agonister og antagonister | |
NO20004778D0 (no) | Amidderivater og nociceptin antagonister | |
NO20032753L (no) | Forbindelse og anvendelse derav | |
NO20011775L (no) | Borefluidadditiver og fremgangsmåter derav | |
DK1454907T3 (da) | Quninazolin og pyridopyrmidin-derivativer | |
DE60031119D1 (de) | Richtbohrvorrichtung und -verfahren | |
IS5667A (is) | 4-bensýlpíperidínalkýlsúlfoxíð-heteróhringir og not þeirra sem undirtegunda-valbundin nmda-þega-mótlyf | |
NO20006488D0 (no) | Sammensetning og anvendelse | |
NO20010804D0 (no) | Muskariniske agonister og antagonister | |
DE59608834D1 (de) | Bohr- und Meisselgerät | |
NO20003449D0 (no) | Sentraliseringsanordning | |
IS4947A (is) | Tróvafloxasín mesýlat tafla | |
NO20004274D0 (no) | Proteaseaktivert reseptor 4 og anvendelse derav | |
DE69921110D1 (de) | Bohrflüssigkeiten und zusatzstoffen | |
NO20013237L (no) | 3,3-biarylpiperidin og 2,2-biarylmorfolinderivater | |
DK1068238T3 (da) | Integrinheterodimer og subunit deraf | |
NO963331D0 (no) | 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister | |
DE69805154T2 (de) | Programmierbares Gerät | |
DK1140952T3 (da) | Phosphororganiske forbindelser og anvendelse heraf | |
ATE272118T1 (de) | T-zell selektive interleukin-4 agoniste | |
NO20003268D0 (no) | Hyperhydrert kitikolin, fremgangsmÕte og anvendelse | |
DE29810384U1 (de) | Programmierbares Gerät | |
DK1127052T3 (da) | Substituerede 2-phenylbenzimidazoler, fremstilling og anvendelse heraf | |
DK1133300T3 (da) | Desmethylolanzapinsammensætninger og fremgangsmåder | |
DK1049777T3 (da) | ACPL-DNA og -polypeptider |